E2 ModerateModerate confidencePEM unclearCross-SectionalPeer-reviewedMachine draft
Symptoms of autonomic dysfunction in chronic fatigue syndrome.
Newton, J L, Okonkwo, O, Sutcliffe, K et al. · QJM : monthly journal of the Association of Physicians · 2007 · DOI
Quick Summary
This study looked at whether people with ME/CFS have problems with their autonomic nervous system (the part that controls automatic body functions like heart rate and blood pressure). Researchers used a questionnaire called COMPASS to measure autonomic symptoms in ME/CFS patients and healthy controls. They found that autonomic dysfunction symptoms were significantly more common in ME/CFS patients and were linked to how severe their fatigue was.
Why It Matters
This study provides empirical evidence that autonomic dysfunction is a common feature of ME/CFS and develops a quantifiable diagnostic criterion (COMPASS >32.5) that could help identify patients who might benefit from targeted autonomic-focused treatments. Understanding the autonomic component of ME/CFS may lead to more personalized therapeutic approaches and better patient stratification in future clinical trials.
Observed Findings
- Autonomic dysfunction symptoms (measured by COMPASS) were strongly and reproducibly more prevalent in CFS patients than in healthy controls across both study phases.
- A COMPASS score threshold >32.5 was identified as a diagnostic cutoff with high positive predictive value (0.96) and good negative predictive value (0.84) for CFS in the validation phase.
- Autonomic dysfunction symptoms correlated with fatigue severity as measured by the Fatigue Impact Scale.
- Autonomic dysfunction was associated with both CFS and primary biliary cirrhosis, suggesting a potential cross-cutting pathophysiological mechanism.
- Not all CFS or PBC patients exhibited autonomic dysfunction, indicating heterogeneity within these conditions.
Inferred Conclusions
- Autonomic nervous system dysfunction is a prominent feature in a substantial subset of ME/CFS patients and correlates with fatigue severity.
- A dysautonomia-associated fatigue (DAF) pathway may represent a distinct aetiological process in both CFS and PBC.
- COMPASS >32.5 is a valid screening criterion for identifying ME/CFS patients with autonomic dysfunction who may be candidates for targeted intervention studies.
- Autonomic dysfunction testing could help stratify ME/CFS patients for personalized treatment approaches.
Remaining Questions
What This Study Does Not Prove
This study does not establish that autonomic dysfunction causes ME/CFS—only that the two are associated. The cross-sectional design prevents determination of temporal relationships or causality. The study also does not prove that all ME/CFS patients have autonomic dysfunction; the authors explicitly note that autonomic dysfunction was not present in all CFS patients studied.
Tags
Symptom:Orthostatic IntoleranceFatigue
Method Flag:PEM Not DefinedWeak Case DefinitionSmall Sample
Metadata
- DOI
- 10.1093/qjmed/hcm057
- PMID
- 17617647
- Review status
- Machine draft
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →